Form PTO-1449								t of Commerce lemark Office		ocket No. ZA/JPW/GJG		al No. 37,341
STPI	- in	<i>''</i>						CITATION	Applica David	nts Baltimore	et a	al.
OGT 9.4		$\left(\left(\left$	se :	sever	al sh	eet	ts if necessa	ary)	Filing Janua:	Date cy 4, 2002		1 of 4
3		E					U.S. PA	TENT DOCUMEN	NTS			
Examine Initial	BMARAL	Doc	cum	ent Nu	mber	F	Date	Name	Class	Subclass	Filing D	
						F	OREIGN	PATENT DOCUM	1ENTS			_
		Docu	1m(ent N	umb	er	Date	Country	Class	nslation		
											Yes	No
					T							
			OT	HER I	OCI	UM	ENTS (Inclu	ding Author, Title, Da	ite, Pertinen	t Pages, Etc.)		
/D.G./								t, Ariad Phar 06cv679 (CMH/I		cals, Inc	z. V.	Jon W.
))								of Hearing, Ar tion 1:06cv67			als,	Inc. V
JO-000000000000000000000000000000000000								dum Of Law In s lternative Fo				
000000000000000000000000000000000000000			ma	ceut				ffs' Motion : V. Jon W. Du				
200000000000000000000000000000000000000	Ì	TO I	nte	erve	ne	Ar	nd For L	nt Regarding eave To File, Action 1:06c	Ariad	Pharmaceu		
300000000000000000000000000000000000000								Of Filing, Antion 1:06cv679			cals,	Inc. V
		Inte	rve	ene	Ву	El	i Lilly	tiffs' Brief and Company, Action 1:06c	Ariad	Pharmaceu		
/D.G./								iffs' Brief Ir lternative For				
							T					
EXAMINE	R	/Dav	vid (Guzo/			DATE CONS	SIDERED 06	/15/2008			
								n is in conformance with M cation to applicant.	PEP 609: Drav	v line through citati	on if not in	1 conformance

Atty. Docket No. Form PTO-1449 Serial No. U.S. Department of Commerce 75723-ZA/JPW/GJG 10/037,341 Patent and Trademark Office Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 2 of 44 **January 4, 2002 U.S. PATENT DOCUMENTS** Date Class Examiner **Document Number** Name Subclass Filing Date Initial if Appropriate FOREIGN PATENT DOCUMENTS **Document Number** Date Country Subclass Translation Class Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Opposition To Plaintiffs' Motion For Summary Judgment, Ariad Pharmaceuticals, Inc. V. Jon W. Dudas, Civil Action 1:06cv679 /D.G./(CMH/BRP) August 28, 2006 Reply Memorandum In Support Of Defendant's Motion To Dismiss, Or, In the Alternative, For Summary Judgment, Ariad Pharmaceuticals, Inc. V. Jon W. Dudas, Civil Action 1:06cv679 October 3, 2006 Order (Defendant's Motion to Dismiss), *Ariad* Pharmaceuticals, Inc. V. Jon W. Dudas, Civil Action 1:06cv679 October 3, 2006 Order (Eli Lilly & Company's Motion to Intervene), Ariad Pharmaceuticals, Inc. V. Jon W. Dudas, Civil Action 1:06cv679 August 2, 2006 Defendant Eli Lilly And Company's Pre-Trial Brief, Ariad Pharmaceuticals, Inc. V. Eli Lilly and Company, Civil Case 02 CV 11280 RWZ 2006 Plaintiffs' Supplemental Trial Brief, Pharmaceuticals, Inc. V. Eli Lilly and Company, Civil Case 02 CV 11280 RWZ September 11, 2006 Plaintiffs' Proposed Findings of Fact and /D.G./ Conclusions of Law on the issues of Inequitable Conduct, EXAMINER DATE CONSIDERED /David Guzo/ 06/15/2008 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Atty. Docket 00373 Strian Und 636 Form PT**O**-1449 **U.S. Department of Commerce** 75723-ZA/JPW/GJG 10/037,341 Patent and Trademark Office Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 3 of 44 **January 4, 2002 U.S. PATENT DOCUMENTS Document Number** Date Class Subclass Filing Date Name Examiner Initial if Appropriate FOREIGN PATENT DOCUMENTS **Document Number** Date Country Class Subclass Translation Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Indefiniteness, Prosecution Laches, and Non-Patentable Subject Matter, Ariad Pharmaceuticals, Inc. V. Eli Lilly and Company, /D.G./ Civil Case 02 CV 11280 RWZ September 11, 2006 Lilly's Post-Trial Proposed Findings Of Fact And Conclusions Of Law Relating To (1) Invalidity Under 35 U.S.C. §101, (2) Unenforceability For Inequitable Conduct, And (3) Unenforceability For Prosecution Laches, Ariad Pharmaceuticals, Inc. V. Eli Lilly and Company, Civil Case 02 CV 11280 RWZ September 29, 2006 Plaintiffs' Reply To Lilly's Proposed Findings of Fact And Conclusions of Law On the Issues of (1) Patentability Under 35 U.S.C. §010, (2) Inequitable Conduct, and (3) Prosecution Laches, Ariad Pharmaceuticals, Inc. V. Eli Lilly and Company, Civil Case 02 CV 11280 RWZ September 29, 2006 Lilly's Response To Ariad's Proposed Findings of Facts And Conclusions of Law, Ariad Pharmaceuticals, Inc. V. Eli Lilly and Company, Civil Case 02 CV 11280 RWZ

April 20, 2006 Civil Cover Sheet, Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action CA

Non-Infringement,

EXAMINER

/David Guzo/

April 20,

Invalidity

And

DATE CONSIDERED

Pharmaceuticals, Inc., Civil Action No.

06/15/2008

2006 Complaint For Declaratory Judgment Of Patent

Amgen,

Inc.

V.

Ariad

10037341 - GALL: 1636

Form PTO-1449

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. 75723-ZA/JPW/GJG Serial No. 10/037,341

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Applicants David Baltimore et al.

Filing Date
January 4, 2002

Page 4 of 44

	(000						y 4, 2002	Page 2	4 01 44			
				U.S. PA	TENT DOCUMENT	rs						
Examiner Initial	Docui	ment N	umber	Date	Name	Class	Subclass	Filing D				
		\perp						<u> </u>				
	<u> </u>			FOREIGN	PATENT DOCUM	ENTS						
1	Docun	nent N	Numbei	Date	Country	Class	Subclass	1				
	+	-тт	T			 	-	Yes	No			
					ding Author, Title, Date							
/D.G./	April Regard	20, ding	2006 a	Report (On The Filing o or Trademark Civil Action	r Deter	cmination gen, Inc.					
200000000000000000000000000000000000000	Dismi: a Cla	ss F im,	or Lac And F	ck of Sub ailure T	t Ariad Pharma oject Matter Ju To Join Indispe <i>ls, Inc</i> ., Civi	risdic ensable	tion, Fail Parties,	lure T <i>Amge</i>	o State			
	June 14, 2006 Declaration of Laurie A. Allen (including ExhibitA-D), Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 0 259-KAJ											
0.0000000000000000000000000000000000000	Memora Subject Relie: (incl	andu ct M f Ma udin	m of i atter y Be g Tab	Law In Su Jurisdi Granted,	nt Ariad Phar upport Of Its M ction, Failure And Failure To gen, Inc. V. A	otion ' To St Join	To Dismis: ate A Cla Indispens	s For im Fo sable	Lack of r which Parties			
		Amg	en, Ii	nc. V. Ar	ion of Paul Ca iad Pharmaceut.							
/D.G./		Amg	en, Iı	nc. V. Ar	ion of Melanie iad Pharmaceut							
EXAMINER	_ /Da	avid G	uzo/	DATE CON	SIDERED	06/15/200	08					

Atty. Docket No. Serial No. Form PTO-1449 U.S. Department of Commerce 75723-ZA/JPW/GJG 10/037,341 Patent and Trademark Office Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 5 of 44 **January 4, 2002 U.S. PATENT DOCUMENTS** Date Class Subclass Filing Date Name Examiner **Document Number** if Appropriate Initial **FOREIGN PATENT DOCUMENTS Document Number** Subclass Translation Date Country Class Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) June 26, 2006 Declaration of Frank Ungemach (including Exhibits /D.G./A-H), Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action No. 1:06-cv-259 (KAJ) June 28, 2006 Plaintiffs' Opposition To Ariad's Motion To Dismiss For Lack of Subject Matter Jurisdiction, Failure To State a Claim, And Failure to Join Indispensable Parties (including Exhibits A-D unreported cases), Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ July 12, 2006 Declaration of Fritz Casselman, Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ July 13, 2006 Declaration of Patricia Carson, Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ 2006 Defendant Ariad Pharmaceuticals, Inc.'s Reply Memorandum of Law In Support of its Motion to Dismiss For Lack of Subject Matter Jurisdiction, Failure to State a Claim For Which Relief May Be Granted, And Failure To Join Necessary And Indispensable Parties, Amgen, Inc. July 12, 2006 Supplemental Declaration of Laurie A. Allen, *Amgen,* /D.G./Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ EXAMINER DATE CONSIDERED /David Guzo/ 1 06/15/2008

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No. Form PTO-1449 U.S. Department of Commerce 75723-ZA/JPW/GJG 10/037,341 Patent and Trademark Office Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 6 of 44 **January 4, 2002** U.S. PATENT DOCUMENTS Class Date Subclass Filing Date Examiner **Document Number** Name Initial if Appropriate FOREIGN PATENT DOCUMENTS **Document Number** Subclass Date Country Class Translation Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Proposed Final Pretrial Order, V.Amgen, Ariad /D.G./ Pharmaceuticals, Inc., Civil Action 06-259-KAJ July 2006 Scheduling 19,, Order, Amgen, Inc. V.Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ 2006 Trial Management Order, V.Amgen, Inc. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ July 21, 2006 Letter to Judge Jordan from Melanie K. Sharp of Young Conaway Stargatt & Taylor, LLP, Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ July 25, 2006 Letter to Judge Jordan from Steven J. Balick of Ashby & Geddes, Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ August 30, 2006 Letter to Judge Jordan from Steven J. Balick of Ashby & Geddes (including Exhibits A & B), Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ August 31, 2006 Letter to Judge Jordan from Melanie K. Sharp of

EXAMINER

/D.G./

/David Guzo/

KAJ

DATE CONSIDERED

06/15/2008

Young Conaway Stargatt & Taylor, LLP (including Exhibits 1 & 2),

Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-

Form PTO-1449

U.S. Department of Commerce Patent and Trademark Office

INFORMATION DISCLOSURE CITATION

Atty. Docket003734	sbrGAUnd63
75723-ZA/JPW/GJG	10/037,341

Applicants

David Baltimore et al.

Filing Date

Page 7 of 44

(Use several sheets if necessary) January 4, 2002 U.S. PATENT DOCUMENTS Class Subclass Examiner **Document Number** Date Name Filing Date if Appropriate Initial **FOREIGN PATENT DOCUMENTS** Document Number Subclass Translation Date Country Class Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) September 13, 2006 Order, Amgen, Inc. V. Ariad Pharmaceuticals, /D.G./ Inc., Civil Action 06-259-KAJ September 25, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Motion Certification Pursuant to 28 U.S.C. §1292(b), Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ September 25, 2006 Defendant Ariad Pharmaceuticals Inc.'s Opening Memorandum of Law In Support of Its Motion For Certification U.S.C. §1292(b), Ariad Pursuant To 28 Amgen, Inc. Pharmaceuticals, Inc., Civil Action 06-259-KAJ 2006 Ariad Pharmaceuticals, Inc.'s Answer September 25, Compliant, Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ September 25, 2006 Declaration of Elizabeth L. Rosenblatt Support of Ariad Pharmaceuticals, Inc.'s Motion For Certification Pursuant To 28 U.S.C. §1292(b) (including Exhibits A-Q), Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ October 2, 2006 Ariad Opposition Ex. A-C, Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ /D.G./ EXAMINER /David Guzo/ DATE CONSIDERED 06/15/2008

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

10037341 - GAU: 1636

Atty. Docket No. Serial No. Form PTO-1449 U.S. Department of Commerce 75723-ZA/JPW/GJG 10/037,341 Patent and Trademark Office Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 8 of 44 **January 4, 2002 U.S. PATENT DOCUMENTS** Examiner **Document Number** Class Subclass Filing Date Name Initial if Appropriate FOREIGN PATENT DOCUMENTS **Document Number** Date Country Class Subclass Translation Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) October 10, 2006 Plaintiffs' Memorandum in Opposition To Ariad's Motion For Certification Pursuant to 28 U.S.C. §1292(b), Amgen, /D.G./ Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ October 10, 2006 Amgen Appendix of Exhibits 1-2 To Pliantiffs' Memorandum in Opposition To Ariad's Motion For Certification 28 U.S.C. §1292(B), Amgen, to Inc. Pharmaceuticals, Inc., Civil Action 06-259-KAJ October 12, 2006 Order, Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ October 17, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Reply Memorandum of Law In Support Of Its Motion For Certification Pursuant To 28 U.S.C. §1292(b), Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ November 3, 2006 Order, Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ 7, 2006 Plaintiffs' First Set of Interrogatories td Defendant, Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ

/D.G./

July 7, 2006 Plaintiffs' First Set of Requests for Production of Documents and Things to Defendant, Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ

EXAMINER

/David Guzo/

DATE CONSIDERED

06/15/2008

Atty. Docket No. Serial No. Form PTO-1449 **U.S. Department of Commerce** 75723-ZA/JPW/GJG 10/037,341 Patent and Trademark Office Applicants David Baltimore et al. INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Filing Date Page 9 of 44 January 4, 2002 **U.S. PATENT DOCUMENTS** Class Subclass Filing Date Date Examiner **Document Number** Name if Appropriate Initial **FOREIGN PATENT DOCUMENTS** Translation Document Number Country Class Subclass Date Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) July 26, 2006 Defendant's Rule 26(a)(1) Initial Disclosure, Amgen, /D.G./Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ July 26, 2006 Plainfiffs' Initial Disclosures Pursuant to Federal Civil Procedure 26(a)(1), Amgen, Inc. V. Ariad Rule of Pharmaceuticals, Inc., Civil Action 06-259-KAJ August 7, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Responses And Objections to Plaintiffs' First Set of Requests For Production of Documents and Things to Defendant, Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ September 27, 2006 Defendant Ariad Pharmaceuticals, Inc.'s First Supplemental Responses And Objections To Plaintiffs' First Set of Requests for Production of Documents And Things to Defendant, Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ August 7, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Responses To Plaintiff And Objections Amgen, Inc.'s First Set of Defendant, V.Interrogatories to Amgen, Inc. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ September 27, 2006 Defendant Ariad Pharmaceuticals, Inc.'s First /D.G./ Supplemental Responses and Objections To Plaintiffs' First Set Of DATE CONSIDERED EXAMINER /David Guzo/ 06/15/2008

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No. Serial No. Form PTO-1449 **U.S. Department of Commerce** 75723-ZA/JPW/GJG 10/037,341 Patent and Trademark Office Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 10 of January 4, 2002|44 U.S. PATENT DOCUMENTS Examine **Document Number** Date Class Subclass Filing Date Name if Appropriate r Initial **FOREIGN PATENT DOCUMENTS Document Number** Date Country Class Subclass Translation Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Requests for Production of Documents and Things to Defendant, Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-/D.G./KAJ October 11, 2006 Defendant Ariad Pharmaceuticals, Inc.'s First Supplemental Responses and Objections to Plaintiff Amgen, Inc.'s First Set of Interrogatories to Defendant, Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ October 26, 2006 Stipulated Protective Order Pursuant To <code>Federal</code> Procedure Ariad Rule Civil 26(c), Amgen, Inc. V.Pharmaceuticals, Inc., Civil Action 06-259-KAJ 2006 Telephone Conference before Honorable Kent Jordan, U.S.D.C.J., Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ September 11, 2006 Motions Hearing before Honorable Kent A. Jordan, U.S.D.C.J., Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ November 3, 2006 Motion Hearing before Honorable Kent A. Jordan, U.S.D.C.J., Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil /D.G./ Action 06-259-KAJ **EXAMINER** DATE CONSIDERED 06/15/2008 /David Guzo/ EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Form PT	O-144		partment of Commerce and Trademark Office	Atty. Docket No. 75723-ZA/JPW/GJG	Serial No. 10/0	37,341
I Inform	IATIO	N DISCLOSURE	CITATION	Applicants David Bal	ltimore et al.	
		if necessary)		Filing Date	Page 11 of 44	
				January 4, 2002		
		I NON I	PATENT LITERATURE DO	CUMENTS		
Examiner Initials	Cite No. ¹		thor (in CAPITAL LETTERS), title of journal, serial, symposium, catalog, et publisher, city and/or country wh	tc.) date, page(s), volumeis:		\mathbb{T}^2
			007 Declaration of Eli	izabeth L. Rose		
/D.G./		Pending Concl Patent and Tr	iad Pharma., Inc.'s Mo Lusion of Reexaminat: ademark Office, Amge , CA No. 06-259-***(N	ion Proceeding n, Inc. et al.	s in the	
990000000000000000000000000000000000000		January 23, 20 Stay Litigat Proceedings i	007 Defendant Ariad Phion Pending Conclusion the Patent and Tr	narma., Inc.'s sion of Reex ademark Office	amination e, Amgen,	
000000000000000000000000000000000000000		Memorandum of Litigation Per in the Patent	007 Defendant Ariad of Law in Support of Relating Conclusion of Relating Trademark Office c. et al. v. Ariad Ph	f Its Motion eexamination Pr (including Ex	to Stay oceedings hibits A-	
		Admission to	2007 Plaintiffs' Firs Defendant, <i>Amgen</i> , , CA No. 06-259 (***)	Inc. et al.		
000000000000000000000000000000000000000		before Hon. Ma Inc. et al. v	2007 Transcript of ary Pat Thynge, U.S. Mr. Ariad Pharma., Inc.	Magistrate Judg ., CA No. 06-2	e, Amgen, 59 (***)	
000000000000000000000000000000000000000	- 1	Set of Reques et al. v. Ari	2007 Defendant Ariad ts for Production of ad Pharma., Inc., CA	No. 06-259-MP	gen, Inc. T	
000000000000000000000000000000000000000		Set of Inter Pharma., Inc.	2007 Defendant Ariad rogatories, Amgen, , CA No. 06-259-MPT	Inc. et al.	v. Ariad	
000000000000000000000000000000000000000		and Objection Admission to <i>Pharma., Inc.</i>	Defendant Ariad Pha s to Plaintiffs' Fir Defendant, Amgen, , CA No. 06-259-MPT	st Set of Required Inc. et al.	uests for v. Ariad	
Y		Set of Reques et al. v. Ari	7 Plaintiffs' Respons ts for Production of ad Pharma., Inc., CA	Documents, Amo No. 06-259-MP	gen, Inc. T	
/D.G.	/	Ariad's First v. Ariad Phar	7 Plaintiffs' Response Set of Interrogators Ma., Inc., CA No. 06-	ies, Amgen, Ind		
EXAMINEI SIGNATUR		/David Guzo/	06/15/2008	•		

^{*}EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line throughation if not in conformance and not considered. Include copy of this form with next communication to applicant pplicant's unique citation designation number (optional) Applicant is to place a checkmark here if English language Translation is attached

Form PT	O-144	9 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. Serial No. 10/075723-ZA/JPW/GJG				
		ON DISCLOSURE CITATION s if necessary)	Applicants David Baltimore et al. Filing Date Page 12 of 44				
-		····	January 4, 2002				
		NON PATENT LITERATURE DOC	CUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of t item (book, magazine, journal, serial, symposium, catalog, etc publisher, city and/or country when	.) date, page(s), volumeissue number(s),	\mathbb{T}^2			
/D.G./		April 3, 2007 Plaintiffs' M (Technology Tutorial), Amgen, In Pharma., Inc., CA No. 06-259-MPT	Multi-Media Materials nc. et al. v. Ariad				
		April 3, 2007 Notice of Filing of (Plaintiffs' Technology Tutorial), Ariad Pharma., Inc., CA No. 06-259	Amgen, Inc. et al. v.				
		April 3, 2007 Notice of Filing of (including Tabs A and B), Amgen, Pharma., Inc., CA No. 06-259-MPT	Inc. et al. v. Ariad				
		April 3, 2007 Ariad Pharma., Inc. Amgen, Inc. et al. v. Ariad Pharma. MPT	, Inc., CA No. 06-259-				
***************************************		April 12, 2007 Defendant Ariad P Supplemental Responses and Objection Set of Interrogatories to Defendant Ariad Pharma., Inc., CA No. 06-259	ns to Plaintiffs' First , <i>Amgen, Inc.</i> et al. v.				
		April 13, 2007 Amended Complaint for of Patent Invalidity and Non-Infrir al. v. Ariad Pharma., Inc., CA No.	ngement, <i>Amgen, Inc. et</i> 06-259-MPT				
***************************************		April 13, 2007 Second Amended Compudgment of Patent Invalidity and Unenforceability, Amgen, Inc. et Inc., CA No. 06-259-MPT	Non-Infringement, and				
		April 13, 2007 Answer to Amended C and Demand for Jury Trial, Amgen, Pharma., Inc., CA No. 06-259-MPT	Inc. et al. v. Ariad				
		April 17, 2007 Letter to Judge 1 Balick, Esq., Amgen, Inc. et al. v CA No. 06-259-MPT					
		April 19, 2007 Defendant and C Ariad's Second Set of Requests for to Amgen, Amgen, Inc. et al. v. A No. 06-259-MPT	Production of Documents				
V		April 20, 2007 Defendant Ariad Supplemental Responses and Objection Set of Requests for Admission to Deal. v. Ariad Pharma., Inc., CA No.	ns to Plaintiffs' First fendant, Amgen, Inc. et 06-259-MPT				
/D.G./		April 23, 2007 Plaintiffs' First and Objections to Ariad's First So Amgen, Inc. et al. v. Ariad Pharma. MPT	et of Interrogatories,				
EXAMINEI	₹ .	: /David Guzo/ 06/15/2008					

*EXAMINER: Initial if citation considered, whether or not citation iniconformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant an unique citation designation number (optional) Applicant is to place a checkmarkhere if English language Translation is attached.

SIGNATURE

Form PT	O-144		epartment of Commerce and Trademark Office	Atty. Docket No. 75723-ZA/JPW/GJG	Serial No. 10/03	37,341						
		ON DISCLOSURE	CITATION	Applicants David Bal								
(Use severa	1 Sneet	s if necessary)		Filing Date January 4, 2002	Page 13 of 44							
		NON I	PATENT LITERATURE DOC	CUMENTS								
Examiner Initials	Cite No.1		Include name of the author (inCAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volumeissue number(s), publisher, city and/or country where published.									
/D.G./		_	Amgen's Technology Tut Pharma., Inc., CA No.	orial, Amgen,	Inc. et							
100000000000000000000000000000000000000			Ariad Pharma., Inc. t al. v. Ariad Pharma.									
000000000000000000000000000000000000000		Mary Pat Thyn	Transcript of Tutoria ge, U.S. Magistrate Jud ma., Inc., CA No. 06-	dge, Amgen, In								
000000000000000000000000000000000000000		and Whitehead	mgen Entities' Reply t 's Counterclaim, <i>Amgen</i> , CA No. 06-259-MPT									
200000000000000000000000000000000000000		hematopoiesis 797	al. (2006) "NF-κB ar ," Cell Death and Dif	ferentiation,	13: 785-							
V		protein kinas	<pre>. (2000) "Cytoplasmic se A mediates cross-re icoid receptor," PNAS</pre>	epression by 1 , 97(22): 1189	NF-κB and 93-11898							
/ /D.G./		From Natura Superdrugs."	t al. "Regulating the Market of the Market o	Rationally book of Trans	Designed scription							
	_											
			Υ									
EXAMINE	.	/David Guzo/	06/15/2008									

*EXAMINER: Initial if citation considered, whether or not tation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant pplicant's unique citation designation number (optional) Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 75723-ZA/JPW/GJG Serial No. 10/037,341

Applicants

David Baltimore et al.

Filing Date Pa January 4, 2002

Page 14 of

(Use several sheets if necessary) Filin Janu H.S. PATENT DOCUMENTS

INFORMATION DISCLOSURE CITATION

January 4, 2002 44											
			U.S. PA	TENT DOCUMEN	TS						
Examiner nitial	Docume	nt Number	Date Name	Class	Subclass		Filing Date if Appropriate				
					<u> </u>						
		I	OREIGN	PATENT DOCUM	IENTS	_					
	Docume	nt Number	Date	Country	Class	Subclass	Tra	slation			
							Yes	No			
						<u> </u>	<u> </u>				
		,		iding Author, Title, Da Dihydroxyvitar							
/D.G./	Nuclear	Translo	cation	α and Synergiz of NFkB during Experimental	g Monocy	ytic Diff	erenti	ation			
/D.G./		in relea		al implication eptic shock",							
/D.G./	Shenep and Mogan, "Kinetics of Endotoxin Relaese During Antibiotic Therapy For Experimental Gram-Negative Bacterial Sepsis", The Journal of Infectious Diseases, Vol. 150, No. 3, (1984) 380-388										
/D.G./	Pharama	ceutical	ls, Inc.	of Facts And v. Eli-Lilly tts, CV-02-11	& Co.,						
EXAMINER	/David G	uzo/	DATE CON	SIDERED 06/	15/2008						

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No. Serial No. Form PTO-1449 U.S. Department of Commerce 75723-ZA/JPW/GJG 10/037,341 Patent and Trademark Office Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Page 15 of 44 Filing Date **January 4, 2002** U.S. PATENT DOCUMENTS Document Number Date Name Class Subclass Filing Date Examiner if Appropriate Initial FOREIGN PATENT DOCUMENTS **Document Number** Translation Date Country Class Subclass Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) April 17, 2007 Deposition of Harvey J. Berger, M.D., Amgen, Inc. /D.G et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT April 20, 2007 Videotaped Deposition of Chen-Ming Fan, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT April 24, 2007 Videotaped Deposition of Jonathan H. Lebowitz, Ph.D., Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT April 27, 2007 Videotaped Deposition of Harinder Singh, Ph.D. Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT May 3, 2007 Videotaped Deposition of Ranjan Sen, Ph.D., Amgen,

/D.G./ Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT

Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil

May 16, 2007 Videotaped Deposition of Phillip A. Sharp, Ph.D.,

EXAMINER

DATE CONSIDERED

Action No. 06-259-MPT

/David Guzo/

06/15/2008

Form PT	'O-1 4	49							-	t of Commerce lemark Office	Atty. D 75723-	ocket No. ZA/JPW/GJG	Seri.	37,341
	INF	OR	MA	T	Oľ	N I	DIS	CI	OSURE C	CITATION	Applica David	nts Baltimore	et a	1.
			(Us	e s	ev	era 	l sh	eet	s if necessa	ary)	Filing Janua r	Date Y 4, 2002		16 of 44
									U.S. PA	TENT DOCUMEN	NTS			
Examiner Initial	Document Number Date								Date	Name	Class	Subclass	Filing D	
						<u> </u>								
								F	OREIGN	PATENT DOCUM	1ENTS			<u></u>
		Do	cun	ne	nt	Nu	mb	er	Date	Country	Class	Subclass	Tra	nslation
													Yes	No
			O	TI	HE	R D	oc	UM	ENTS (Inclu	ding Author, Title, Da	te, Pertinen	t Pages, Etc.)		-
/D.G./	E	Ph.	D.	,	An	nge	en,	I	nc. et a	ed Deposition al. v. Ariad E o. 06-259-MPT	of Alb Pharmace	ert S. B auticals,	aldwi Inc.	n, Jr. et al.
000000000000000000000000000000000000000	Z	\mg	en	,	Ir	nc.	е	t a		d Deposition Ariad Pharmace 9-MPT				
	5	up Int	pl er:	en rc	ner oga	nta ato	ıl ori	Re es	sponses To De	nt Ariad Pha and Objection efendant, Amg et al., D. Del	s To Pla jen, In	aintiffs' c. et al	First	Set O
1	S F	lup leg	pl ue:	en st	ner :s	nta Fo	ıl or	Re	sponses mission	nt Ariad Pha And Objection To Defendant,	s To Pla	aintiff's	First	t Set of

EXAMINER /David Guzo/ Date Considered 06/15/2008

/D.G./

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

May 30, 2007 letter to Judge Thynge from Melanie K. Sharp of Young Conaway Stargatt & Taylor, LLP, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT Form PTO-1449 Atty. Docket No. U.S. Department of Commerce Serial No. 75723-ZA/JPW/GJG Patent and Trademark Office 10/037.341 Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 17 of 44 January 4, 2002 U.S. PATENT DOCUMENTS Examiner **Document Number** Class Subclass Filing Date Name Initial if Appropriate **FOREIGN PATENT DOCUMENTS Document Number** Date Country Class Subclass Translation Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) May 31, 2007 letter to Judge Thynge from Steven J. Balick of Ashby & Geddes, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et /D.G./ al., D. Del. Civil Action No. 06-259-MPT 2007 Wyeth's Reply To Ariad Pharmaceuticals, Massachusetts Institute of Technology, The President And Fellows /D.G./ of Harvard College, and The Whitehead Institute for Biomedical Research's Counterclaim, Amgen, Inc. et al. Ariad v. Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT June 14, 2007 Amgen Entities' Second Supplemental Responses And Objections To Ariad's First Set of Interrogatories: NOS. 1, 2, 5, /D.G./ 6 & 12, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT Abramson, S. et al., "Modes of action of aspirin-like drugs" /D.G./ Proc. Natl. Acad. Sci. USA (1985) 82:7227-7231 Baeuerle, P.A., "The Inducible Transcription Activator NF-kB: Regulation by Distinct Protein Subunits", Biochimica Biophysica. /D.G./ Acta. (1991) 1072:63-80

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

06/15/2008

DATE CONSIDERED

EXAMINER

/David Guzo/

Form PTO-1449 Atty. Docket No. U.S. Department of Commerce Serial No. 75723-ZA/JPW/GJG Patent and Trademark Office 10/037.341 Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 18 of 44 January 4, 2002 **U.S. PATENT DOCUMENTS Document Number** Class Subclass Filing Date Examiner Name f Appropriate Initial FOREIGN PATENT DOCUMENTS **Document Number Subclass** Date Class Translation Country Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) "Two Transcription Factors, Baldwin, A.S., NF-kB and H2TF1. Interact With a Single Regulatory Sequence In the Class I major Histocompatibility Complex Promoter", Proc. Natl. sci. USA, (1988) /D.G./ 85:723-727 Beutler, B. et al., "Control of Cachectin (Tumor Necrosis Factor) Synthesis: Mechanisms of Endotoxin Resistence", Science (1986) /D.G./ 232:977-980

Stranded Phosphorothicate Oligonucleotides", Science (1990)/D.G./ 250:997-1000 Brini, A.T., et al., "Cyclosporin A inhibits induction of IL-2 receptor lpha chain expression by affecting activation of NF- κ B-like factor)s) in cultured human T lymphocytes", Eur. Cytokine Net. /D.G./ (1990) 1:131-139 Chedid, M. And Mizel, S.B., "Involvement of Cyclic AMP-Dependent Protein Kinases the Signal Transduction Pathway in

Bielinska, A. et al., "Regulation of Gene Expression with Double-

Interleukin-1" Molecular And Cellular Biology (1990) 10:3824-3827

EXAMINER

/D.G./

/David Guzo/

DATE CONSIDERED

06/15/2008

Form PTO-1449 INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 75723-ZA/JPW/GJG

10/037,341

Applicants

David Baltimore et al.

Filing Date January 4, 2002 Page 19 of 44

						<u> </u>	January	7 4, 2002			
	· · · · · · · · · · · · · · · · · · ·				U.S. PA	TENT DOCUMEN	NTS				
Examiner Initial	Doci	ument	Num	ber	Date Name	Class	Subclass	Filing Da			
		_							<u> </u>		
<u> </u>			11	F	OREIGN	PATENT DOCUM	MENTS	<u> </u>			
	Docu	ment	Nui	mber	Date	Country	Class	Subclass	Tran	slation	
	- 		1 1						Yes	No	
	+		+		1			<u> </u>			
			┦┦								
						lding Author, Title, Da	. 5 .:	<u> </u>	.11		
/D.G./ /D.G./	Colston, K. et al. "1, 25-Dihydroxyvitamin D3 and Malignant Melanoma: The Presence of Receptors and Inhibition of Cell Growth in Culture" Endocrinology (1981) 108:1083-1086 Devary, Y. et al., "NF-KB Activation by Ultraviolet Light Not Dependent on a Nuclear Signal" Science (1993) 261:1442-1445										
/D.G./	amino	sa	alic	cylic		of remission : in high dose 24					
/D.G./	Admin	nist	rat	ion	of Cimet	"Is Ethanol idine and Rani 1984) 31:35-3	itidine				
/D.G./	Eck, S.D. et al., "Inhibition of Phorbol Ester-Induced Cellular Adhesion by Competitive Binding of NF-κB In Vivo" Molecular and Cellular Biology (1993) 13:6530-6536										
EXAMINER	/D:	avid G	auzo/	/	DATE CON	SIDERED 0	6/15/2008				

Serial No. Atty. Docket No. Form PTO-1449 U.S. Department of Commerce 75723-ZA/JPW/GJG 10/037,341 Patent and Trademark Office Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 20 of 44 January 4, 2002 **U.S. PATENT DOCUMENTS** Date Class Subclass Filing Date Examiner **Document Number** Name Initial if Appropriate FOREIGN PATENT DOCUMENTS **Document Number** Country Class Subclass Translation Date Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Edbrooke, M.R. et al., "Identification of cis-Acting Sequences Responsible for Phorbol Ester Induction of Human Serum Amyloid A Gene Expression via a Nuclear Factor kB-Like Transcription Factor" /D.G./ Molecular and Cellular Biology (1989) 9:1908-1916 Emmel, E.A. et al., "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation" Science (1989) 246:1617-1620 /D.G./ Giri, J.G. et al., "Interleukin 1-Mediated Induction of κ-Light **Chain Synthesis And Surface** Immunoglobulin Expression of Pre-B Cells" The Journal of Immunology (1984) 132:223-228 /D.G./ Gray, T.K. et al., "17β-Estradiol acts directly on the clonal osteoblastic cell line UMR106" Proc. Natl. Acad. Sci. USA (1987) /D.G./ 84:6267-6271 Griffith [1], B.P., et al., "Targeted blood levels of cyclosporine for cardiac transplantation" J. Thorac Cardiovasc Surg (1984) 88:952-957 /D.G./ Griffith al., [2], B.P., et "Cardiac Transplantation with Cyclosporin A and Prednisone" Ann. Surg. (1982) 196:324-329 /D.G./ DATE CONSIDERED 06/15/2008 EXAMINER /David Guzo/

Atty. Docket No Form PTO-1449 U.S. Department of Commerce 75723-ZA/JPW/GJG 10/037,341 Patent and Trademark Office Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 21 of 44 **January 4, 2002 U.S. PATENT DOCUMENTS** Class Subclass Filing Date Examiner **Document Number** Date Name Initial if Appropriate FOREIGN PATENT DOCUMENTS **Document Number** Date Country Class Subclass Translation Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Hahn, E.O. et al., "Effect of Cortisone on Acute Streptococcal Infections And Post-Streptococcal Complications1 Streptococcal /D.G./ Disease Laboratory (1950) pp. 274-281 al., Holick, M.F. et "Identification of 1,25/D.G./ Dihydroxycholecalciferol, a Form of Vitamin D, Metabolically Active in the Intestine" Proc. Nat. Acad. Sci. USA (1971) 68:803-804 Hoyos, B. Et al., "Kappa B-Specific DNA Binding Proteins: Role in the Regulation of Human Interleukin-2 Gene Expression" Science /D.G./ (1989) 244:457-460 Jones, A.W., "Elimination Half-life of Methanol During Hangover" /D.G./ Pharmacology & Toxicology (1987) 60:217-220 Kohase, M. et al., "Dexamethasone Inhibits Feedback Regulation of the Mitogenic Activity of Tumor Necrosis Factor, Interleukin-1, /D.G./ and Epidermal Growth Factor in Human Fibroblasts" Journal of Cellular Physiology (1987) 132:271-278

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Receptor Expression in Human Leukemic T-Cell Line,

et al.,

Cellular Immunology (1986) 103:469-475

DATE CONSIDERED

Koizumi,

/David Guzo/

/D.GL/

EXAMINER

"Inhibitors of IL-2 Production and IL-2

06/15/2008

10037841 - CAU: 1636 Form PTO-1449 Atty. Docket No. U.S. Department of Commerce Serial No. 75723-ZA/JPW/GJG Patent and Trademark Office 10/037.341 Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 22 of 44 January 4, 2002 **U.S. PATENT DOCUMENTS** Class Filing Date Examine Document Number Name Subclass r Initial if Appropriate FOREIGN PATENT DOCUMENTS Document Number Class Subclass Translation Date Country Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Kovacs, E.J., et al., "Differential Inhibition of IL-1 and TNF-c mRNA Expression By Agents Which Block Second Messenger Pathways In Murine Macrophages¹" The Journal of Immunology (1988) 141:3101-/D.G./ 3105 Krönke, M. et al., "Cyclosporin A Inhibits T-cell Growth Factor /D.G./ Gene Expression At the Level of mRNA Transcription", Proc. Natl. Acad. Sci. USA (1984) 81:5214-5218 Lawson, D.E.M., et al., "Identification of 1,25-Dihydroxycholecalciferol, a New Kidney Hormone controlling Calcium /D.G./Metabolism" Nature (1971) 230:228-230 /D.G. Lemire, J.M., et al., "1,25-Dihydroxyvitamin D, Suppresses Human T Helper/Inducer Lymphosyte Activity in Virto1" The Journal of Immunology (1985) 134:3032-3035

/D.G./

Lemire [2], J.M. et al., " 1α ,25-Dihydroxyvitamin D_3 Suppresses Proliferation and Immunoglobulin Production by Normal Human Peripheral Blood Mononuclear Cells", J. Clin. Invest. (1984) 74:657-661

EXAMINER

/David Guzo/

DATE CONSIDERED

06/15/2008

Form PTO-1449 U.S. Department of Commerce Atty. Docket No. Serial No. 757**23-ZA/JPW/GJG** Patent and Trademark Office 10/037.341 Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 23 of 44 January 4, 2002 **U.S. PATENT DOCUMENTS** Date Class Examiner Document Number Subclass Filing Date Initial if Appropriate FOREIGN PATENT DOCUMENTS **Document Number** Subclass Class Translation Date Country Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Lipsky, P.E. et al., "The Role of Interleukin 1 in Human B Cell Activation: Inhibition of B Cell Proliferation and the Generation of Immunoglobulin-Secreting Cells By An Antibody Against Human /D.G./ Leukocytic Pyrogen'" The Journal of Immunology (1983) 130:2708-2714 "Inhibition of Nonspecific Tumoricidal Männel, D.N., et al., Activity by Activated Macrophages with Antiserum Against a Soluble /D.G./ Cytotoxic Factor" Infection And Immunity (1981) 33:156-164 [1], S.C. et al., "The Antiproliferative Effect of Calcitriol on Human Peripheral Blood Mononuclear Cells" Journal of Clinical Endocrinology and Metabolism (1986) 63:394-400 /D.G./ Manolagas [2], S.C. et al., Estrogen, Cytokines, and the Control of Osteoclast Formation and Bone Resorption In Vitro and In Vivo" /D.G./ Osteoporosis Int (1993) Suppl. 1:S114-116 /David Guzo/ DATE CONSIDERED EXAMINER 06/15/2008

							-	t of Commerce lemark Office	10037841 - G/At Atty. Docket No. Serial No. 75723-ZA/JPW/GJG 10/037,341					
I	NFC)RM	[A]	OIT	N I	OISC	LOSURE (CITATION	Applicants David Baltimore et al.					
		(U	Jse s	sev	eral	shee	ets if necess	ary)	Filing Dat January	e 4, 2002	Page 24 of 44			
							U.S. PA	TENT DOCUMEN	ITS					
Examiner Initial		Doc	cum	ent !	Num	ber	Date	Name	Class	Subclass	Filing D			
	_	-	┡	-										
	1	1	<u> </u>	<u> </u>			 FOREIGN	PATENT DOCUM	TENTS	<u> </u>				
	1	Doci	ıme	ent	Nu	mber		Country	Class	Subclass	Translation			
						T					Yes	No		
	-	-							-		1			
	_	╁		┢	\vdash				_	1				
<u> </u>			OT	HEI	R De	CIIN	MENTS (Incl.	l Iding Author, Title, Da	te Pertinen	t Pages Ftc.)				
	M							Human Monocyt			Fumor	Cells:		
/D.G./	C	ont	ril	but	cio	n o		acellular Cyt						
	M	att	he	ws	[2	2],	N., "Ef	fect on human	monocy	te killi	ng of	tumour		
/D.G./	C	ell	S	of	: ;	anti	.body ra	aised against (1983) 48:321	an ex	ktracellu]	lar m	onocyte		
	Νı	ucl	ear	r	Fa	ctoi	к в by	rotein Kinase Tumor Necro 1990) 265:833	sis Fac					
/D.G./							· · · · · · · · · · · · · · · · · · ·							
(5.0)	C		ro.	ls	DN.	A-B	inding Ad	ge, W., "Introttivity of NF- ics, German Ca	кВ-Like	Protein(s)" In	stitute		
/D.G./	\perp													
/D.G./	a							Inhibition of nd cysteine de						
EXAMINER		,			 Guzo	. /	DATE CON	SIDERED	06/15/2008					

Atty. Docket No. Serial No. Form PTO-1449 U.S. Department of Commerce 75723-ZA/JPW/GJG 10/037,341 Patent and Trademark Office Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 25 of 44 **January 4, 2002 U.S. PATENT DOCUMENTS** Examiner **Document Number** Date Name Class Subclass Filing Date Initial if Appropriate FOREIGN PATENT DOCUMENTS **Document Number** Date Country Class Subclass Translation No Yes OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Miller, H.R. et al., "Reduction of Nonspecific Fluorescence in Respiratory Specimens By Pretreatment with N-Acetylcysteine" /D.G./ Journal of Clinical Microbiology (1986) 24:470-471 Mukaida, N. et al., "Novel Mechanism of Glucocorticoid-Mediated Gene Repression", The Journal of Biological Chemistry (1994) 269:13289-13295 /D.Gl Nagasawa, K. et al., "Inductio of Human Malignanat T-Lymphoblastic Cell Lines MOLT-3 and Jurkat by 12-0-Tetradecanoylphorbol-13-Ciochemical, Physical, and Morphological Characterization" Journal of Cellular Physiology (1981) 109:181-/D.G./ 192 A.W. al., "1,25-Dihydroxycholecalciferol: Norman, et Identification of the Proposed Active Form of Vitamin D, in the /D.**G**./ Intestine" Science (1971) 173:51-54 Osborn, L. et al., "Tumor necrosis factor lpha and interleukin stimulate the human immunodeficiency virus enhancer by activation /D.G./ of the nuclear factor kB" Proc. Natl. Acad. Sci. USA (1989) 86:2336-2340 EXAMINER DATE CONSIDERED 06/15/2008 /David Guzo/

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Serial No. Form PTO-1449 Atty. Docket No. U.S. Department of Commerce 75723-ZA/JPW/GJG 10/037,341 Patent and Trademark Office Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 26 of **44** January 4, 2002 **U.S. PATENT DOCUMENTS** Examiner **Document Number** Date Class Filing Date Subclass Name Initial if Appropriate FOREIGN PATENT DOCUMENTS **Document Number** Date Country Class Subclass **Translation** Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Provvedini, D.M. et al., "1,25-Dihydroxyvitamin D, Receptors in /D.G./ Humna Leukocytes" Science (1983) 221:1181-1183 Reed, J.C. et al., "Effect of Cyclosporin A and Dexamethasone on Interleukin 2 Receptor Gene Expression¹" The Journal of Immunology /D.G./ (1986) 137:150-154 Reed [2], J.C. et al., "Regulation of c-myc mRNA levels in normal human lymphocytes by modulators of cell proliferation" Proc. Natl. Acad. Sci. USA (1985) 82:4221-4224 /D.G./ Rigby [1], W.F.C. et al., "Regulation of Lymphokine Production and Human T Lymphocyte Activiation by 1, 25-Dihydroxyvitamin D." J. /D.G./ Clin. Invest. (1987) 79:1659-1664 Rigby [2], W.F.C. et al., "The Effects of 1,25-Dihydroxyvitamin D₃ on Human T Lymphocyte Activation and Proliferation: A cell

EXAMINER

/D.G./

/D.G./

/David Guzo/

DATE CONSIDERED

Acad. Sci. USA (1990) 87:4884-4888

06/15/2008

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

cycle analysis" The Journal of Immunology (1985) 135:2279-2286

Roederer, M. et al., "Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine" Proc. Natl.

Form PTO-1449 Atty. Docket No. **U.S. Department of Commerce** Serial No. 75723-ZA/JPW/GJG **Patent and Trademark Office** 10/037.341 Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 27 of 44 January 4, 2002 U.S. PATENT DOCUMENTS Class Examine **Document Number** Name Subclass Filing Date r Initial if Appropriate FOREIGN PATENT DOCUMENTS **Document Number** Subclass **Translation** Date Country Class Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) "Induction of Differentiation et al., Promyelocytic Leukemia Cells by Tumor Promoters" Science (1979) 204:868-870 /D.G./ Ruben and Rosen, "Suppression of Signals Required for Activation of Transcription Factor NF-kB in Cells Constitutively Expressing the HTLV-I Tax Protein" The New Biologist (1990) 2:894-902 /D.G./Saito [Article], Y. et al., "Possible involvement of a novel in neurite outgrowth of PC12 cells" Neuroscience protease /D.G./ Research, Suppl. 13 (1990) S97-S101 Saito [1], Y. et al., "Enhancement of neurite outgrowth in PC12h

EXAMINER

/D.G.l/

/D.G./

107

Saito

/David Guzo/

[2], Y.

(1989) 106:1035-1040

DATE CONSIDERED

06/15/2008

et al., "The Neurite-Initiating Effect

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

cells by a protease inhibitor" Neuroscience Letters (1988) 89:102-

Tripeptide Aldehyde Pretease Inhibitor on PC12h Cells" J. Biochem.

10037341 GAU: 1636 Form PTO-1449 Atty. Docket No. Serial No. U.S. Department of Commerce 75723-ZA/JPW/GJG Patent and Trademark Office 10/037.341 Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 28 of 44 January 4, 2002 U.S. PATENT DOCUMENTS Date Class Subclass Filing Date Examiner **Document Number** Name Initial if Appropriate FOREIGN PATENT DOCUMENTS Translation Document Number Date Country Class Subclass Yes $\mathbb{N}_{\mathbf{0}}$ OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Scheinman, R. et al., "Characterization of Mechanisms Involved In Transrepression of NF-kB by Activated Glucocorticoid Receptors", /D.G./ Molecular and Cellular Biology (1995) 15:943-953 Schmidt, A. et al., "Inducible Nuclear Factor Binding to the KB Elements of the Human Immunodeficiency Virus Enhancer in T Cells Can Be Blocked by Cyclosporin A in a Signal-Dependent Manner", /D.G./ Journal of Virology (1990) 64:4037-4041 Schreck [1], R. et al., "Dithiocarbamates as Potent Inhibitors of Nuclear Factor kB Activation in Intact Cells" J. Exp. Med. (1992) /D.G./ 175:1181-1194 "Reactive Schreck [2], R. et al., oxygen intermediates /D.G./ apparently widely used messengers in the activation of the NF-xB transcription factor and HIV-1" The EMBO Journal (1991) 10:2247-2258

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

al.,

 D_3 " Tetraheddron Letters No. 40 (1972) 4147-4150

"The

06/15/2008

Dihydroxycholecalciferol - A Metabolically Active Form of Vitamin

Synthesis

οf

 $1\alpha, 25-$

Semmler,

/David Guzo/

/D.G./

EXAMINER

E.J.

et

DATE CONSIDERED

Atty. Docket No. Form PTO-1449 U.S. Department of Commerce Serial No. 757**23-ZA/JPW/GJG** Patent and Trademark Office 10/037.341 Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 29 of 44 January 4, 2002 U.S. PATENT DOCUMENTS Examiner Document Number Date Class Subclass Filing Date Name Initial if Appropriate FOREIGN PATENT DOCUMENTS **Document Number** Subclass **Translation** Date Country Class Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Shirakawa and Mizel, "In Vitro Activation and Nuclear Translocation of NF-kB Catalyzed by Cyclic AMP-Dependent Protein Kinase and Protein Kinase C", Molecular and Cellular Biology /D.G./ (1989) 9:2424-2430 Siebenlist, U. et al., "Promoter Region of Interleukin-2 Gene Undergoes Chromatin Structure Changes and Confers Inducibility on /D.G./ Chloramphenicol Acetyltransferase Gene during Activation of Cells" Molecular and Cellular Biology (1986) 6:3042-3049 St. Ledger, et al., "Factors Associated With Cardiac Morality In /D.G./ Developed Countries With Particular Reference To The Consumption of Wine", Public Health, The Lancet (1979) 1017-1020 Staal, F.J.T. et al., "Intracellular Thiols Regulate Activation /D.G./of Nuclear Factor κB and Transcription of Human Immunodeficiency Virus", Proc. Natl. Acad. Sci. USA (1990) 87:9943-9947 Tanaka, H. et al., "Sequence-specific interaction of α - β -anomeric /D.G./ couble-stranded DNA with the p50 subunit of NF- κ B: application to the decoy approach" Nucleic Acids Research (1994) 22:3069-3074

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

/David Guzo/

EXAMINER

06/15/2008

,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,														
Form PT	TO-1	449					•	t of Commerce lemark Office		ocket No. A/JPW/GJG	Serial No. 10/037,341			
	INI	ORM	MA]	ГΙΟ	N DI	SCI	LOSURE (CITATION	Applicants David Baltimore et al.					
							ts if necess:	:	Filing Date Page 30 of 44 January 4, 2002					
							U.S. PA	TENT DOCUMEN	ITS					
Examiner Initial	aminer Document Number Date Name								Class		Filing Date if Appropriate			
									<u>. l</u>					
						F	OREIGN	PATENT DOCUM	IENTS	7 · · · · · · · · · · · · · · · · · · ·				
		Doc	ume	ent	Num	ber	Date	Country	Class	Subclass	Tra	nslation		
											Yes	No		
			ОТ	HE	R DOC	CUM	ENTS (Inclu	iding Author, Title, Da	te, Pertinen	t Pages, Etc.)				
/D.G./		Spec (199	eif 90)	ic 2:	Inh : 793	ibi -80	itor of	Long Termina Phosphatases t al., "Sign	1 and 2	2A" The N	ew Bi	ologist		
/D.G./		Sur	Eac	e	Prot	ei	ns, TCR	/CD3 And CD28 ournal of Imm	3, Acti	vates The	HIV.	-1 Long		
/D.G./			/en	t	sept			"Anti-cachect during lethal						
/D.G./		Tsou Immu	ıka ıno	s, reg	C. gula	D. tor	et al ry Hormo	, "1,25-Dih ne" Science (ydrosyv 1984) 22	itamin D 24:1438-14) ₃ : A	. Novel		
/D.G./		Waage and Bakke, "Glucocorticoids suppress the production of tumour necrosis factor by lipoplysaccharide-stimulated human monocytes" Immunology (1988) 63:299-302												
EXAMINE	ER	//	David	d Gi	uzo/		DATE CON	SIDERED	06/15/20	08				

						,	100			
Form PTO	-1449		-	t of Commerce emark Office	Atty. Do	ocket No. ZA/JPW/GJG	Seria 10/03	1 No.		
I)	NFORMA	TION DIS	SCLOSURE C	CITATION	Applicants David Baltimore et al.					
	(Use	several sh	eets if necessa	ary)	Filing Januar	Date Y 4, 2002		31 of 44		
			U.S. PA	TENT DOCUMEN	NTS					
Examiner Initial	Docur	nent Number	Date	Name	Class	Subclass	Filing Date if Appropriate			
			<u> </u>							
	·		FOREIGN	PATENT DOCUM	MENTS	Ţ	,			
	Docum	ent Numb	er Date	Country	Class	Subclass	Trai	nslation		
							Yes	No		
			<u> </u>							
· · · · · · · · · · · · · · · · · · ·	O	THER DOC	UMENTS (Inclu	ding Author, Title, Da	ate, Pertinent	t Pages, Etc.)				
/D.G./	by whi range	ch this of eff	venerable ects have	e After more to drug and its yet to be so pp. 84-90	relativ	ves achiev	ve the	ir wide		
/D.G./	Physic	cians' D	esk Refer	ence 1970 24 th	Edition	n				
/D.G./	Physic	cians' D	esk Refer	ence 1980 34 th	Edition	n				
/D.G./	Physic	cians' D	esk Refer	ence 1985 39 th	Edition	n	-			
		· · · · · · · · · · · · · · · · · · ·								
EXAMINER	/David G	Guzo/	DATE CON	SIDERED	06/15/2	008				

Form PTO-1449

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 75723-ZA/JPW/GJG Serial No. 10/037,341

(Use several sheets if necessary)

Applicants David Baltimore et al.

	J)	Jse :	sever	al shee	ts if necess:	ary)		Date ry 4, 2002	Page 3	32 of 44
					U.S. PA	TENT DOCUME	NTS			
Examiner Initial	Do	cum	ent Nu	mber	Date	Name	Class	Subclass	ate opriate	
			Ш.							
					FOREIGN	PATENT DOCUM	MENTS			-
	Doc	ume	ent Ni	ımber	Date	Country	Class	Subclass	Tra	nslation
									Yes	No
<u></u>				<u> </u>		<u> </u>				
	<u> </u>			•		iding Author, Title, D				
/D.G./	Amge	n,	Inc	. et		on of Lynn C Ariad Pharmace 9-MPT				
/D.G./	201,	Ar	ngen	, Inc	e. et al.	on of Roger Gr v. Ariad Pha 06-259-MPT				
/D.G./	Ph.D	٠.,	Pag	es 1-	275, Am	aped Deposition of Section N	al. v. A	Ariad Phan		
/D.G./	Ph.D	٠,	Vol	. I-	II, Amge	taped Deposit en, Inc. et a ivil Action N	1. v. A	riad Phar		
/D.G./	Inte	rre	ogat	ories	(Nos.	's Response 1-25), Amg et al., D. Del	en, Ind	c. et al	rst L. v. D. 06-	Ariad
EXAMINER		/Dav	vid Gu	zo/	DATE CON	SIDERED	06/15/2008			

10037 Serial No. Form PTO-1449 Atty. Docket No. U.S. Department of Commerce 75723-ZA/JPW/GJG 10/037,341 **Patent and Trademark Office** Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 33 of 44 **January 4, 2002** U.S. PATENT DOCUMENTS Date Filing Date Examiner Document Number Name Class Subclass Initial if Appropriate FOREIGN PATENT DOCUMENTS **Document Number** Date Country Class Subclass Translation Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) July 9, 2007 Ariad And The Institutions' Responses And Objections To Amgen Entities' Second Set Of Interrogatories, Amgen, Inc. et al. /D.G./ Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT August 17, 2007 Wyeth's Supplemental Responses To Ariad's First Set Of /D.G./ Interrogatories (Nos. 1-25), Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT September 10, 2007 Wyeth's Second Set of Supplemental Responses To Ariad's First Set Of Interrogatories (Nos. 1-25), Amgen, Inc. et al. /D.G Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT Annual Meeting, J. Am. Med. Assoc. (1963) 183:166-169 /D.G./ Baeuerle and Baltimore, "IkB: A Specific Inhibitor of the NF-kB Transcription Factor", Science (1988a) 242:540-546 /D.G./

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

217

/David Guzo/

/D.G./

EXAMINER

Baeuerle and Baltimore, "Activation of DNA-Binding Activity in an Apparently Cytoplasmic Precursor of the NF-xB Transcription Factor", Cell (1988b) 53:211-

/David Guzo/

Form PTO-1449					Department of t and Tradem		Atty. Docket No. 75723-ZA/JPW/GJG 10/037,341				
II					LOSURE CIT		Applicants David Ba	ltimore et al.			
		(Use	severa	al shee	ets if necessary	y) 	Filing Date January 4		Page 3	34 of 44	
					U.S. P.	ATENT DOCUMENTS					
Examiner Initial	Do	cume	ent Numl	ber	Date	Name	Name Class Subcla		Filing Date if Appropriate		
	++	H		┼┼			-	<u> </u>		<u></u>	
				LL.	FOREIG	N PATENT DOCUMEN	its				
	Doc	ume	nt Nun	nber	Date	Country	Class	Subclass	Tra	nslation	
					<u> </u>				Yes	No	
	\perp			igspace							
	$\bot \bot$			Ш	<u></u>		<u> </u>				
						iding Author, Title, Date					
T	ransc	cri	ption	Fac	tor Invol	"Phorbol-ester-in ves Dissociation d Spring Harbor Sy	of an A	pparently (Cytopla	smic NF-	
/D.G./ ti	he P	ron	noter	of	The Mouse	ing of a Nuclear F e H-2K ^b Class I logy (1987) 7:305-	Major :	o a Regulat Histocompat	ory Sec	ruence in y Gene",	
/D.G./	altir	nor	e, D.	, "I	ntracellul	lar immunization",	, Nature	: (1988) 335	5:395-3	96	
/D.G./ Ex	itoge	en-: cer	Induc Elem	ed A	Activation	ne Immunosuppressa of the Interkeu and NF-AT1", Molec	ıkin-2 F	romoter an	d the	Isolated	
ir	nterí	fer	M.A. on re :1139	spon	se sequenc	gamma-interferon ce of the MHC clas	-induced s I gene	i factor te, H-2Kb", T	that bi	inds the) Journal	
EXAMINER /	David	 I Gu			DATE CONSI	DERED 06/15/20	08				

FOREIGN PATENT DOCUMENTS Document Number Date Country Class Subclass Translation Yes No											т		T		
David Baltimore et al. Filing Date Page 35 of 44 Filing Date Page 35 of 44 Page 3															
U.S. PATENT DOCUMENTS Document Number Date Name Class Subclass Filing Date Inditial		IN										ltimore et al.			
Document Number Date Name Class Subclass Filing Date If Appropriate				(Use	e sev	vera	l she	ets	if necessary	y) 			Page 3	35 of 44	
FOREIGN PATENT DOCUMENTS Document Number Date Country Class Subclass Translation Yes No									U.S. P	ATENT DOCUMENTS	;				
Document Number Date Country Class Subclass Translation Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Bohnlein E. et al., "The Same Inducible Nuclear Proteins Regulates Mitoger Activation of Both the Interleukin-2 Receptor-Alpha Gene and Type 1 HIV", Cell (1988) 53:827-836 Clouse, K.A. et al., "Monokine Regulation of Human Immunodeficiency Virus-1 Expression in a Chronically Infrected Human T Cell Clone", The Journal of Immunology (1989) 142:431-438 Collart, M.A. et al., "Modulations of Functional Activity in Differentiated Macrophages are Accompanied by Early And Translent Increase or Decrease in c-FOS Gene Transcription", The Journal of Immunology (1987) 139:949-955 Collart, M.A. et al., "Regulation of Tumor Necrosis Factor Alpha Transcription in Macrophages: Involvement of Four xB-Like Motifs and of Constitutive and Inducible Forms of NF-kB", Molecullar and Cellular Biology (1990) 10:1498-1506 Cross, S.L. et al., "Functionally Distinct NF-kB Binding Sites in the Immunoglobulin x and IL-2 Receptor a Chain GEnes", Science (1989) 244:466-469 EXAMINER /David Guzo/ DATE CONSIDERED OG/15/2008	Examiner Initial		Do	eum	ent N	Yuml)er		Date	Name	Class	Subclass			
Document Number Date Country Class Subclass Translation Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Bohnlein E. et al., "The Same Inducible Nuclear Proteins Regulates Mitoger Activation of Both the Interleukin-2 Receptor-Alpha Gene and Type 1 HIV", Cell (1988) 53:827-836 Clouse, K.A. et al., "Monokine Regulation of Human Immunodeficiency Virus-1 Expression in a Chronically Infrected Human T Cell Clone", The Journal of Immunology (1989) 142:431-438 Collart, M.A. et al., "Modulations of Functional Activity in Differentiated Macrophages are Accompanied by Early And Translent Increase or Decrease in c-FOS Gene Transcription", The Journal of Immunology (1987) 139:949-955 Collart, M.A. et al., "Regulation of Tumor Necrosis Factor Alpha Transcription in Macrophages: Involvement of Four xB-Like Motifs and of Constitutive and Inducible Forms of NF-kB", Molecullar and Cellular Biology (1990) 10:1498-1506 Cross, S.L. et al., "Functionally Distinct NF-kB Binding Sites in the Immunoglobulin x and IL-2 Receptor a Chain GEnes", Science (1989) 244:466-469 EXAMINER /David Guzo/ DATE CONSIDERED OG/15/2008				\bigsqcup	Ш	Ш		ightharpoonup							
Document Number Date Country Class Subclass Translation Yes No						Ш		\perp				<u> </u>	_1		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Bohnlein E. et al., "The Same Inducible Nuclear Proteins Regulates Mitoger (1988) 53:827-836 D.G./ Clouse, K.A. et al., "Monokine Regulation of Human Immunodeficiency Virus-1 Expression in a Chronically Infrected Human T Cell Clone", The Journal of Immunology (1989) 142:431-438 Collart, M.A. et al., "Modulations of Functional Activity in Differentiated Macrophages are Accompanied by Early And Transient Increase or Decrease in c-FOS Gene Transcription", The Journal of Immunology (1987) 139:949-955 (Collart, M.A. et al., "Regulation of Tumor Necrosis Factor Alpha Transcription in Macrophages: Involvement of Four xB-Like Motifs and of Constitutive and Inducible Forms of NF-xB", Molecullar and Cellular Biology (1990) 10:1498-1506 (Cross, S.L. et al., "Functionally Distinct NF-xB Binding Sites in the Immunoglobulin x and IL-2 Receptor α Chain GEnes", Science (1989) 244:466-469									FOREIGN	N PATENT DOCUMEN	₹TS	- ₁			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Bohnlein E. et al., "The Same Inducible Nuclear Proteins Regulates Mitogen Activation of Both the Interleukin-2 Receptor-Alpha Gene and Type 1 HIV", Cell (1988) 53:827-836 Clouse, K.A. et al., "Monokine Regulation of Human Immunodeficiency Virus-1 Expression in a Chronically Infrected Human T Cell Clone", The Journal of Immunology (1989) 142:431-438 Collart, M.A. et al., "Modulations of Functional Activity in Differentiated Macrophages are Accompanied by Early And Transient Increase or Decrease in c-FOS Gene Transcription", The Journal of Immunology (1987) 139:949-955 Collart, M.A. et al., "Regulation of Tumor Necrosis Factor Alpha Transcription in Macrophages: Involvement of Four κΒ-Like Motifs and of Constitutive and Inducible Forms of NF-κΒ", Molecullar and Cellular Biology (1990) 10:1498-1506 Cross, S.L. et al., "Functionally Distinct NF-κΒ Binding Sites in the Immunoglobulin κ and IL-2 Receptor α Chain GEnes", Science (1989) 244:466-469 EXAMINER /David Guzo/ DATE CONSIDERED O6/15/2008			Doc	:umc	ent l	Nun	ıber		Date	Country	Class	Subclass	Tra	nslation	
Bohnlein E. et al., "The Same Inducible Nuclear Proteins Regulates Mitogen Activation of Both the Interleukin-2 Receptor-Alpha Gene and Type 1 HIV", Cell (1988) 53:827-836 Clouse, K.A. et al., "Monokine Regulation of Human Immunodeficiency Virus-1 Expression in a Chronically Infrected Human T Cell Clone", The Journal of Immunology (1989) 142:431-438 Collart, M.A. et al., "Modulations of Functional Activity in Differentiated Macrophages are Accompanied by Early And Transient Increase or Decrease in c-FOS Gene Transcription", The Journal of Immunology (1987) 139:949-955 Collart, M.A. et al., "Regulation of Tumor Necrosis Factor Alpha Transcription in Macrophages: Involvement of Four kB-Like Motifs and of Constitutive and Inducible Forms of NF-kB", Molecullar and Cellular Biology (1990) 10:1498-1506 Cross, S.L. et al., "Functionally Distinct NF-kB Binding Sites in the Immunoglobulin k and IL-2 Receptor a Chain GEnes", Science (1989) 244:466-469 EXAMINER /David Guzo/ DATE CONSIDERED O6/15/2008		$-\!\!\!\!\!+$						4		<u></u>		↓	Yes	No	
Bohnlein E. et al., "The Same Inducible Nuclear Proteins Regulates Mitogen Activation of Both the Interleukin-2 Receptor-Alpha Gene and Type 1 HIV", Cell (1988) 53:827-836 D.G.		$-\!$	igspace	\sqcup	\square		$oxed{oldsymbol{\perp}}$	\dashv				<u> </u>			
Bohnlein E. et al., "The Same Inducible Nuclear Proteins Regulates Mitogen Activation of Both the Interleukin-2 Receptor-Alpha Gene and Type 1 HIV", Cell (1988) 53:827-836 D.G.			₩	igspace	\square		$\vdash \vdash$	\dashv							
Bohnlein E. et al., "The Same Inducible Nuclear Proteins Regulates Mitogen Activation of Both the Interleukin-2 Receptor-Alpha Gene and Type 1 HIV", Cell (1988) 53:827-836 Clouse, K.A. et al., "Monokine Regulation of Human Immunodeficiency Virus-1 Expression in a Chronically Infrected Human T Cell Clone", The Journal of Immunology (1989) 142:431-438 Collart, M.A. et al., "Modulations of Functional Activity in Differentiated Macrophages are Accompanied by Early And Transient Increase or Decrease in c-FOS Gene Transcription", The Journal of Immunology (1987) 139:949-955 Collart, M.A. et al., "Regulation of Tumor Necrosis Factor Alpha Transcription in Macrophages: Involvement of Four kB-Like Motifs and of Constitutive and Inducible Forms of NF-kB", Molecullar and Cellular Biology (1990) 10:1498-1506 Cross, S.L. et al., "Functionally Distinct NF-kB Binding Sites in the Immunoglobulin k and IL-2 Receptor a Chain GEnes", Science (1989) 244:466-469 EXAMINER /David Guzo/ DATE CONSIDERED O6/15/2008			Ш	ليا	ليا	ليا									
Activation of Both the Interleukin-2 Receptor-Alpha Gene and Type 1 HIV", Cell (1988) 53:827-836 Clouse, K.A. et al., "Monokine Regulation of Human Immunodeficiency Virus-1 Expression in a Chronically Infrected Human T Cell Clone", The Journal of Immunology (1989) 142:431-438 Collart, M.A. et al., "Modulations of Functional Activity in Differentiated Macrophages are Accompanied by Early And Transient Increase or Decrease in c-FOS Gene Transcription", The Journal of Immunology (1987) 139:949-955 Collart, M.A. et al., "Regulation of Tumor Necrosis Factor Alpha Transcription in Macrophages: Involvement of Four kB-Like Motifs and of Constitutive and Inducible Forms of NF-kB", Molecullar and Cellular Biology (1990) 10:1498-1506 Cross, S.L. et al., "Functionally Distinct NF-kB Binding Sites in the Immunoglobulin k and IL-2 Receptor a Chain GEnes", Science (1989) 244:466-469 EXAMINER /David Guzo/ DATE CONSIDERED O6/15/2008	<u> </u>													883 45 2 2 2 2	
Clouse, K.A. et al., "Monokine Regulation of Human Immunodeficiency Virus-1 Expression in a Chronically Infrected Human T Cell Clone", The Journal of Immunology (1989) 142:431-438 Collart, M.A. et al., "Modulations of Functional Activity in Differentiated Macrophages are Accompanied by Early And Transient Increase or Decrease in c-Fos Gene Transcription", The Journal of Immunology (1987) 139:949-955 Collart, M.A. et al., "Regulation of Tumor Necrosis Factor Alpha Transcription in Macrophages: Involvement of Four κB-Like Motifs and of Constitutive and Inducible Forms of NF-κB", Molecullar and Cellular Biology (1990) 10:1498-1506 Cross, S.L. et al., "Functionally Distinct NF-κB Binding Sites in the Immunoglobulin κ and IL-2 Receptor α Chain GEnes", Science (1989) 244:466-469 EXAMINER David Guzo/ DATE CONSIDERED 06/15/2008	/D.G./	Act	tiv	rati	ion	of	Bot	:h	, "The the Inte	Same Inducible Nurleukin-2 Recepto	or-Alpha	Gene and Ty	gulates /pe 1 H:	IV", Cell	
Expression in a Chronically Infrected Human T Cell Clone", The Journal of Immunology (1989) 142:431-438 Collart, M.A. et al., "Modulations of Functional Activity in Differentiated Macrophages are Accompanied by Early And Transient Increase or Decrease in c-FOS Gene Transcription", The Journal of Immunology (1987) 139:949-955 Collart, M.A. et al., "Regulation of Tumor Necrosis Factor Alpha Transcription in Macrophages: Involvement of Four κB-Like Motifs and of Constitutive and Inducible Forms of NF-κB", Molecullar and Cellular Biology (1990) 10:1498-1506 Cross, S.L. et al., "Functionally Distinct NF-κB Binding Sites in the Immunoglobulin κ and IL-2 Receptor α Chain Genes", Science (1989) 244:466-469 Cross															
Macrophages are Accompanied by Early And Transient Increase or Decrease in c-FOS Gene Transcription", The Journal of Immunology (1987) 139:949-955 Collart, M.A. et al., "Regulation of Tumor Necrosis Factor Alpha Transcription in Macrophages: Involvement of Four κΒ-Like Motifs and of Constitutive and Inducible Forms of NF-κΒ", Molecullar and Cellular Biology (1990) 10:1498-1506 Cross, S.L. et al., "Functionally Distinct NF-κΒ Binding Sites in the Immunoglobulin κ and IL-2 Receptor α Chain GEnes", Science (1989) 244:466-469 EXAMINER /David Guzo/ DATE CONSIDERED 06/15/2008	/D.G./	Ex	pre	essi	ion	ir	ı a	Ch	nronicall	ly Infrected Huma	of Humar an T Cel	Immunodef	iciency The Jo	/ Virus-1 ournal of	
Macrophages are Accompanied by Early And Transient Increase or Decrease in c-FOS Gene Transcription", The Journal of Immunology (1987) 139:949-955 Collart, M.A. et al., "Regulation of Tumor Necrosis Factor Alpha Transcription in Macrophages: Involvement of Four κΒ-Like Motifs and of Constitutive and Inducible Forms of NF-κΒ", Molecullar and Cellular Biology (1990) 10:1498-1506 Cross, S.L. et al., "Functionally Distinct NF-κΒ Binding Sites in the Immunoglobulin κ and IL-2 Receptor α Chain GEnes", Science (1989) 244:466-469 EXAMINER /David Guzo/ DATE CONSIDERED 06/15/2008															
in Macrophages: Involvement of Four κB-Like Motifs and of Constitutive and Inducible Forms of NF-κB", Molecullar and Cellular Biology (1990) 10:1498-1506 Cross, S.L. et al., "Functionally Distinct NF-κB Binding Sites in the Immunoglobulin κ and IL-2 Receptor α Chain GEnes", Science (1989) 244:466-469 EXAMINER /David Guzo/ DATE CONSIDERED 06/15/2008	/D.G./	Mad	cro	pha	ages	s a	re A	Acc	companied	d by Early And Tra	ansient	Increase or	Decre	ase in c-	
in Macrophages: Involvement of Four κB-Like Motifs and of Constitutive and Inducible Forms of NF-κB", Molecullar and Cellular Biology (1990) 10:1498-1506 Cross, S.L. et al., "Functionally Distinct NF-κB Binding Sites in the Immunoglobulin κ and IL-2 Receptor α Chain GEnes", Science (1989) 244:466-469 EXAMINER /David Guzo/ DATE CONSIDERED 06/15/2008															
/D.G. Immunoglobulin κ and IL-2 Receptor α Chain GEnes", Science (1989) 244:466-469 EXAMINER /David Guzo/ DATE CONSIDERED 06/15/2008	/D.G./	in	Ma	acro	oph	age	es:	In	volvemen	t of Four kB-Lik	ce Motif	s and of C	onstitu	itive and	
/D.G. Immunoglobulin K and IL-2 Receptor a Chain GEnes", Science (1989) 244:466-469 EXAMINER /David Guzo/ DATE CONSIDERED 06/15/2008															
EXAMINER /David Guzo/ DATE CONSIDERED 06/15/2008	/D.G./			•											
/David Gu20/ U6/15/2008								一,	DATE CONSI	INEDED					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance	EXAMINER				/Da	avid	Guzo	o/	DATE CONSI	06/15	5/2008				
	*EXAMINER:	Initial i	if cita	ation	cons	sidere	ed, wh	ethe	er or not citation	on is in conformance with MI	PEP 609: Dra	w line through cita	tion if not i	n conformance	

Form PTO-14	149					epartment of (Atty. Docke 75723-Z	et No. A/JPW/GJG	Serial N 10/037,2		
	INI					LOSURE CIT		Applicants David Ba	altimore et al.	•		
		(i 	Use se	evera	al sheet	ts if necessary	·)	Filing Date January		Page :	36 of 44	
						U.S. PA	ATENT DOCUMENTS	s				
Examiner Initial		Doci	ument	Numi	ber	Date	Name	Class	Subclass	Filing Da		
	$\perp \perp \rfloor$	\sqcup	\bot	'	igsqcup							
		Ш		'					<u> </u>			
						FOREIGN	PATENT DOCUME	NTS				
	,	Docui	ment	Nun	nber	Date	Country	Class	Subclass	Tra	anslation	
										Yes	No	
		\Box	ightharpoons						i			
		\Box										
		0	THE	RD	OCUN	AENTS (Inclu	ding Author, Title, Da	te, Pertinen	it Pages, Etc.)			
/D.G./		vis,	N.	et	al.,	, "Rel-Ass	sociated pp40: A ence (1991) 253:	n Inhibi	itor of the	Rel F	amily of	
ļ												
/D.G./							nce of remission s by mouth", Brit					
/D.G./	Ant Vit	timi	crob and	bial In-	. Ager	nts on Endo	, "Effects of Di lotoxin Release f Scandinavian Jour	rom Gram	-negative B	Bacteri	a: An In-	
								*				
/D.G./	rec	n, Cl quire	ed :	Min for	ig and huma	d Maniatis an β-inter	g, T., "Two differ feron gene regu	erent vii	rus-inducib The EMBO	le elem Journa	ments are	
/D.G./	ser	para	ted	zin	ic fir		, T., "A DNA-bin s that recognize					
EXAMINER	/Da	vid G	auzo/	/		DATE CONSIL	DERED 06/15/20	008			-	

Form PT	0-1	449	. •				-	t of Commerce lemark Office	Atty. Docket No. Serial No. 75723-ZA/JPW/GJG 10/037,341					
	INE	ORN	ИΑΊ	MOL	DIS	CI	OSURE C	CITATION	Applica David	_{nts} Baltimore	e et a	1.		
							s if necess:		Filing		Page 3	37 of 44		
							U.S. PA	TENT DOCUMEN	NTS					
Examiner Initial		Do	cum	ent Nu	mber		Date	Name	Class	Subclass	Filing D			
		<u>L I.</u> .												
						F	OREIGN	PATENT DOCUM	1ENTS					
		Doc	ume	ent Nu	ımb	er	Date	Country	Class	Subclass	Tra	nslation		
										Yes	No			
			ОТ	HER I	OC	UM	ENTS (Inclu	ding Author, Title, Da	ite, Pertinen	t Pages, Etc.)				
/D.G./		кВ k	ур		ess:	ing	g of p10	atis, T., "Gen 5 through an A						
/D.G./		act:	iva	tor	se.	le	ctively	"Expression impedes lyti 335:452-454						
/D.G./		pent die:	i-1 nyll	-eny benz	lbe ene	nz	ene and New Inhi	cloepoxydon, d 1-Hydroxy-2 bitors of Euk tics (1998) 5	2-hydrox aryotic	cymethyl-3 Signal Tr	3- p ent	: - 1, 3-		
/D.G./		tumo	or .	necr	osi	s	factor	iatis, T., °C α and interfo USA (1989) 8	eron β	cells and				
/D.G./		regu	ıla	tion	by	7 1		l., "Human to nd lipopolysa 9-9773						
	一			····										
														
EXAMINE	R	/	Davi	d Guz	 o/		DATE CON	sidered 06/	15/2008					

Form P	ΓΟ- 1	1449				•	t of Commerce lemark Office	Atty. D 75723-	ocket No. ZA/JPW/GJ0	Seria 3 10/03	1 No. 37,341	
	IN:						CITATION	Applica David	nts Baltimor	e et a	1.	
		(Us	e sev	veral	sheet	ts if necess:	ary)	Filing Janua:	Date Ty 4, 200	Page 3	38 of 4	
						U.S. PA	TENT DOCUME	NTS				
Examiner Initial		Docu	ment	Num	ber	Date	Name	Class	Subclass	Filing D		
72000	<u> </u>	<u> </u>			F	OREIGN	PATENT DOCU	IMENTS				
		Docu	nent	Nui		Date		Class	Subclass	Trai	nslation	
		<u> </u>								Yes	No	
			THE	R DO	<u> CUM</u>	ENTS (Inclu	ding Author, Title, D	ate, Pertinen	t Pages, Etc.)			
/D.G./		Goodb negat Natl.	ive	reg	gula	tory dom	ntiatis, T., mains of the h 1988) 85:1447	uman β-i:	lapping parterferon	positi gene"	ve an , Proc	
/D.G./		Induc	ed	in	Adhe	al., "Cherent Mo 1261-12	naracterizati onocytes That 89	on of an Encode:	Immediat s IxB-lik	te-Ear	ly Gen ivity"	
/D.G./		quant	ifi	cat.	ion (of inter	and direct m leukin-1 rece munological M	ptors us	ing 96 we	11 fil	tratio	
/D.G./	:.	Chron	ica	lly	Ba	cteriuri	Antibiotic-In ic Patients" :2388-2394	duced Re , Antim	lease of	Endote Agen	oxin i	
/D.G./		facto	r t	hat	bin	ds to a	tis, T., "Id positive red c. Natl. Acad	gulatory	element	of the	e human	
										-		

DATE CONSIDERED

/D.G.

EXAMINER

/David Guzo/

Kerr, L.D. et al., "The Rel-associated pp40 protein prevents DNA binding of Rel and NF- κ B: relationship with I κ B β and regulation

06/15/2008

by phosphorylation", Genes and Development (1991) 5:1464-1476

341 - GAU: 1636 Form PTO-1449 Atty. Docket No. U.S. Department of Commerce Serial No. 75723-ZA/JPW/GJG Patent and Trademark Office 10/037.341 Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 39 of 44 January 4, 2007 U.S. PATENT DOCUMENTS Date Examine **Document Number** Class Subclass Name Filing Date r Initial if Appropriate **FOREIGN PATENT DOCUMENTS Document Number** Date Country Class Subclass Translation Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) al., St. Ledger, A.S. et "Factors Associated With Cardiad Mortality In Developed Countries With Particular Reference To The Consumption of Wine", The Lancet (1979) 1017-1020 /D.G./ Lenardo, M. et al., "Protein-Binding Sites in Ig Gene Enhancers Determine Transcriptional Activity and Inducibility", Science (1987) 236:1573-1577 /D.G. Lenardo, M.J. et al., "NF-kB protein purification from bovine spleen: Nucleotide stimulation and binding site specificity", Proc. Natl. Acad. Sci. USA (1988) 85:8825-8829 /D.G./ Lenardo, M.J. et al., "The Involvement of NF- κ B in β -Interferon Gene Regulation Reveals Its Role as Widely Inducible Mediator of /D.G./ Signal Transduction", Cell (1989) 57:287-294 Leung, Κ. and Nabel, G., "HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kB-like factor", Nature (1988) 333:776-778 /D.G./

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

06/15/2008

DATE CONSIDERED

EXAMINER

/David Guzo/

								nt of Commerce demark Office	10037341 - GAU:				
	INF							CITATION		Baltimore et a			
		,, 	USC:	seve	:raı	Snee-	ets if necessa	ary)	Filing Dat January	te y 4, 2002	Page 4	40 of 44	
					_	_	U.S. PA	TENT DOCUMEN	TS				
Examiner Initial		Do	œum	nent N		ber	Date	Name	Class	Subclass	Filing D		
	\dashv	+	\dotplus	+-	\dashv	_			 	-	<u> </u>		
1			1_	Ш			FOREIGN	PATENT DOCUM	ENTS	1			
		Doc	:um	ent]	Nun	mber	T	Country	Class	Subclass	ass Translation		
	\Box										Yes	No	
					\Box				1				
,		\top		\prod		T	1.				1		
			от	HEF	₹ DC	OCUM	1ENTS (Inclu	uding Author, Title, Date	te. Pertinen	t Pages, Etc.)		<u></u>	
/D.G./	t	to t	eat, the	re	'. e 21/1	et a: NF-χ	l., "Inh xB family	nibition of trainsdom y by a transdom :1827-1832	nscript	tion facto	rs be	longing	
	+												
1	l ^M	laux rar	cion	n, rip	F.	et Tal	al., "	Comparison of cement mediate	consti	itutive a	nd in	ducible	
	M	10du	ılat	tio:	n c	of a	activity	in B cells by	human	T-cell le	eukemi	a virus	
/D.G./	t	.ype	i E	ta	хç	jene	", Proc	. Natl. Acad. S	Sci. US	SA (1991)	88:21	41-2145	
	<u>r</u>	laux	cio	n, !	F.	And	Sen, R.	, "Alteration o	of a Si	ngle Nucle	eotide	Allows	
/D.G./	E	Effi	icie	ent	: Bi	indi	ing of H2	2TF1/KBF1 to the	he Immu	inoglobuli	in ĸ E	hhancer	
, , , , , ,	۴	Pic	<u>/L.s.</u>	<u> </u>	Pic	<u>)160</u>	Ular am	d Cellular Bio	Logy (1	1989) 9:35	348-35	552	
					<u>—</u>	24	1	"Townsod E	· - 3 - 4 - 5 - 1	' т.			
_]	C	Conc	cent	tra	ıtic	ons	in Cere	"Increased En brospinal Flui	id of 1	Infants w	ith Co	coliform	
/D.G./	M G	ſeni	ing: :ami	iti: ici:	s n :	and Ther	Ventri	culitis Associ	iated w	with Intr	cavent	ricular	
	广	60.	<u>دره</u>	1-0	95								
	\top					-							
EXAMINER	<u> </u>	/Da	ıvid (Guzo	 э/		DATE CONS	SIDERED 06	6/15/2008				

Pat INFORMATION DIS								t and Trad	t of Commerce lemark Office CITATION	Applicant	ket No. A/JPW/GJG	10/03/,541		
								s if necessa	=	Filing Dat		1	11 of 44	
								U.S. PA	TENT DOCUMEN				·	
Examiner nitial		D	ocum	en	t Nu	mbei		Date	Name	Class	Subclass	Filing D		
		+	-		+	-	-							
		I .	-	٠		Т.	F	OREIGN	PATENT DOCUM	1ENTS		· 		
	ł	Doc	um	en	t N	umb	er	Date	Country	Class	Subclass	Trai	nslation	
				_								Yes No		
				L				·						
			1	L	_ _	_	L							
								<u></u>						
									e, D., "An in					
/D.G./ /D.G./	ē	Tati	iva ure sen	te , bl	es (19 B. Le	exp 87) et Tr	al	ssion of 26:711-	human immuno	deficie	ncy virus	in T	cells"	
	10 10 10 10 10 10 10 10 10 10 10 10 10 1	Jel:	sen luli	, blar Wil	B. Le W.F	exp 87) et Tr iol	al ans	ssion of 26:711-	F human immuno 713 NF-KB-Binding on in Nonlymp	g Site Mo	ediates Phells", Mo	norbol	Ester	
	A A A A A A A A A A A A A A A A A A A	Jelsindi Jel	sen luli by, 5-D 145	, blar Will-W	B. Le B. W.F. Flyd	et Triol	all ans.og	ssion of 26:711-1	F human immuno 713 NF-KB-Binding on in Nonlymp 8:3526-3531	Site Monday Control Co	ediates Phells", Mo	norbololecul togen vest.	Ester and esis by (1984	

06/15/2008

DATE CONSIDERED

/David Guzo/

EXAMINER

Form PT	O-144	9		_			•	at of Commerce demark Office		ocket No. ZA/JPW/GJG		al No. 37,341
	INFO	RM.	ΑT	Oľ	N D)IS(CLOSURE C	CITATION	Applica David	nts Baltimore	et a	al.
		(Us	ie s	eve	ral	she	eets if necess	ary)	Filing I Januar	Date ry 4, 2002		42 of 44
							U.S. PA	TENT DOCUMENT	TS			
Examiner Initial		Docu	ıme	ent N	lumi	ber	Date	Name	Class	Subclass	Filing D	
L		Щ	\Box	\Box	\perp							
· · · · · · · · · · · · · · · · · · ·							FOREIGN	PATENT DOCUMI	ENTS			
	D)ocur	me	nt l	Nur	nbe	er Date	Country	Class	Subclass	Tra	nslation
											Yes	No
		$\perp \perp$		Ш								
		<u>C</u>	<u>TT</u>	HER	L DC	<u>)CU</u>	MENTS (Inclu	uding Author, Title, Date	e, Pertinen	t Pages, Etc.)		
/D.G./								"Proteins con l", Trends in C				
/D.G./								rle, P., "A reends in Cell B				
/D.G./								D., "Multiple N ancer Sequence:				
/D.G./	En	ìhan	ıce	er-	Biı	ndi	Baltimore ing Protei 7:921-928	e, D., "Induci in NF-ĸB by a Po	bility osttran	of κ Imuslational	munog . Mech	lobulin anism",
/D.G./	Du	ırin	ig i	Ant	tib	oio	tic Thera	an, K.A., "Kin apy For Experime f Infectious D	ental Gr	ram-Negati	ive Ba	cterial
EXAMINE	R	/Da	— avid	d Gu	zo/		DATE CON	SIDERED 06/	(15/2008			

											- I	49-17 1 49-1 1 49-	
Form PT	rO-1	449					-	t of Commerce lemark Office	Atty. D 75723-	ocket No. Z A/JPW/ GJG	Seria 10/03	al No. 37,341	
	INF	ORM	[AT]	ION	DIS	CL	OSURE (CITATION	Applica David	^{nts} Baltimore	e et a	1.	
		(U	se s	evera	al sh	eet	s if necess:	ary)	Filing Januar	Date y 4, 2002		43 of 44	
							U.S. PA	TENT DOCUME	NTS				
Examiner Initial		Doc	ume	nt Nu	mber		Date	Name	Class	Subclass	Filing D		
							L						
	г т					F	OREIGN	PATENT DOCUM	MENTS		<u> </u>		
		Docu	me	nt Ni	ımb	er	Date	Country	Class	Subclass	Tra	nslation	
		1		- 1		r—-					Yes	No	
				<u> </u>		L							
	гт		OTH	IER I	OC	UM	ENTS (Inclu	ding Author, Title, D	ate, Pertinen	t Pages, Etc.)			
/D.G./								G.P., "Searc cience (1990)			Ligan	ds with	
/D.G./	1	Arth: Olig	rit ode	is oxy	By nuc	I: le	n Vivo	Suppressed S Transfection As A Gene The	of Nuc	lear Fact	or kl	B Decoy	
/D.G./		acti	vat	ed	hun	nan	lympho	down-regulati cytes by 1,2 1995) 92:1099	5-dihydr				
/D.G./		Disso	oci	ate	th	e (Complex	e, P.A., "Pu of the NF-kB 90) 61:255-26	Transcri				
/D.G./			ons	Ad	ljac			entification he Human β-In					
						_							
EXAMINE	L CR	/1	Davi	d Guz	zo/		DATE CON	SIDERED 06/	15/2008				

Atty. Docket No. Serial No. Form PTO-1449 U.S. Department of Commerce 75723-ZA/JPW/GJG Patent and Trademark Office 10/037,341 Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 44 of 44 **January 4, 2002** U.S. PATENT DOCUMENTS Examiner Date **Document Number** Name Class Subclass Filing Date Initial if Appropriate FOREIGN PATENT DOCUMENTS **Document Number** Date Country Class Subclass Translation Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) July 16, 2007 Memorandum In Support of Eli Lilly And Company's Motion To Stay Entry of Judgement Pending Reexamination or For Settlement of Form of Final Judgement, Document 409, filed 07/16/2007, pgs. 1-18 in Civil Case 02 CV 11280 RWZ /D.G./ August 22, 2007 Reply Memorandum In Support of Eli Lilly And Company's Motion To Stay Entry of Judgement Pending Reexamination or For Settlement of Form of Final Judgement. /D.G./ Document 414, filed 08/22/2007, pgs. 1-11, including Exhibits 2-6 in Civil Case 02 CV 11280 RWZ September 10, 2007 Final Judgement, Document 417, filed 09/10/2007, pgs. 1-5 in Civil Case 02 CV 11280 RWZ /D.G./ September 23, 2007 Memorandum In Support of Defendant's Renewed Motion For Judgment As A Matter Of Law Or, In The Alternative, A New Trial, Document 420, filed 09/23/2007, /D.G./ pgs. 1-53, including Exhibit 2 in Civil Case 02 CV 11280 RWZ July 16, 2007 Declaration Of Laura P. Masurovsky For Eli Lilly And Company's Motion To Stay Entry Of Judgment Pending Reexamination Or For Settlement Of Form of Final Judgment, Document 410, filed 07/16/2007, pgs. 1-2, including Exhibits 2-13 in Civil Case 02 /D.G./ CV 11280 RWZ July 26, 2007 Plaintiffs' Opposition To Lilly's Motion To Stay Entry Of Judgment Pending Reexamination or for Settlement of Form of Final Judgement, Document 411, filed /D.G./ 07/26/2007, pgs. 1-11, including Exhibit 2 in Civil Case 02 CV 11280 RWZ **EXAMINER** DATE CONSIDERED 06/15/2008 /David Guzo/